A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
暂无分享,去创建一个
K. Götze | P. Fenaux | A. Symeonidis | A. Giagounidis | U. Platzbecker | V. Santini | A. Anagnostopoulos | R. Schlag | E. Olíva | M. A. Spiriti | R. Wapenaar | A. Potamianou | L. Gercheva‐Kyuchukova | A. Radinoff | M. H. Berger | H. Haralampiev | I. Milionis | L. Gercheva-Kyuchukova
[1] M. Delforge,et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.
[2] H. Deeg,et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] G. Mufti,et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Ganser,et al. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study , 2014, European journal of haematology.
[5] P. Vyas,et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.
[6] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[7] G. Barosi,et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. , 2010, Leukemia research.
[8] D. Cella,et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.
[9] L. Malcovati,et al. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome , 2009, Haematologica.
[10] J. Reeves,et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.
[11] David P Steensma,et al. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. , 2006, Leukemia research.
[12] R. Tehranchi. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes , 2006, Medical oncology.
[13] I. Dybedal,et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. , 2005, Blood.
[14] I. Dybedal,et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Commentary , 2005 .
[15] R. Latagliata,et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome , 2005, Annals of Hematology.
[16] Nikolaos Laoutaris,et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients , 2002, British journal of haematology.
[17] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[18] V. Diehl,et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin , 2000, British journal of haematology.
[19] N. Piva,et al. A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes , 1998, British journal of haematology.
[20] P. Greenberg,et al. Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.
[21] L. Lessin,et al. The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS) , 1995, British journal of haematology.
[22] W. Vainchenker,et al. Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. , 1987, Blood.